UK scientists at the University of Oxford are accelerating development of a vaccine for Bundibugyo ebolavirus, one of the rarest and deadliest known strains. The virus kills approximately one in three infected people, and no proven vaccine currently exists.
The research team plans to move into human trials within months, leveraging existing vaccine platform technology developed during the COVID-19 pandemic. This approach uses messenger RNA and viral vector methods already proven safe in millions of people globally, which dramatically shortens the typical vaccine development timeline.
Bundibugyo represents a distinct threat in the Ebola family. Unlike Zaire ebolavirus, which caused the devastating 2014-2016 West African epidemic, Bundibugyo remains confined primarily to Central Africa. The strain emerges sporadically in Uganda and the Democratic Republic of Congo, making large-scale outbreaks less common but no less lethal when they occur.
The UK team's rapid development strategy reflects lessons learned from COVID vaccine creation. Rather than starting from scratch, scientists adapted proven delivery mechanisms to target Bundibugyo's genetic structure. This modular approach has compressed what traditionally takes a decade into a matter of months.
Funding and regulatory support from UK health authorities underscore growing recognition that rare disease preparedness requires proactive investment. The strategy acknowledges that waiting for major outbreaks before developing countermeasures leaves populations vulnerable during critical early transmission windows.
If trials proceed as planned, the vaccine could enter clinical testing by mid-year. Success would mark the first approved preventive treatment for this particular strain and strengthen global capacity to respond to emerging filovirus threats. The work also positions the UK as a leader in rapid-response vaccine development for neglected tropical diseases.